AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30001903 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (manual therapy + motor control exercises + inspiratory muscle training)
Number of subjects: 51
Study 30001903 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 51
Study 27296490 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg oral methotrexate weekly
Number of subjects: 43
Study 27296490 — intervention group
Group type: COMPARATOR
Intervention: 1 g mycophenolate mofetil twice daily
Number of subjects: 43
Study 27296490 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 43
Study 24497828 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-7 administration (recombinant human IL-7 at 20 µg/kg, three subcutaneous injections)
Number of subjects: 23
Study 24497828 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-7 administration
Number of subjects: 23
Study 24349532 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐18 ‐607A/C polymorphism (A/A homozygotes) among alcohol consumers
Number of subjects: 1126
Study 24349532 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐18 ‐137 polymorphism (G/C heterozygotes)
Number of subjects: 1126
Study 24349532 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to oral cancer-related environmental risk factors (areca, alcohol, tobacco)
Number of subjects: 1126
Study 24349532 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐18 ‐137 G/C alleles
Number of subjects: 1126
Study 20934561 — intervention group
Group type: EXPERIMENTAL
Intervention: silent MI
Number of subjects: 5733
Study 20934561 — intervention group
Group type: EXPERIMENTAL
Intervention: HxMI
Number of subjects: 5733
Study 20934561 — intervention group
Group type: COMPARATOR
Intervention: no prior MI
Number of subjects: 5733
Study 18237588 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP) at cuff pressures of 300 mm Hg
Number of subjects: 21
Study 18237588 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment at cuff pressures of 75 mm Hg
Number of subjects: 21
Study 18237588 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP) and Sham treatment
Number of subjects: 21
Study 16901294 — intervention group
Group type: EXPERIMENTAL
Intervention: Health screening intervention
Number of subjects: 100
Study 16901294 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 100
Study 12627927 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) for outpatients
Number of subjects: 100
Study 12627927 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin for inpatients
Number of subjects: 100
Study 11802676 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature Biofeedback (N = 81)
Number of subjects: 313
Study 11802676 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG Biofeedback (N = 74)
Number of subjects: 313
Study 11802676 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Temperature Biofeedback (N = 46)
Number of subjects: 313
Study 11802676 — intervention group
Group type: COMPARATOR
Intervention: Behavioral Control Procedure (frontalis EMG biofeedback)
Number of subjects: 313
Study 11802676 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine-XL
Number of subjects: 313
Study 11802676 — intervention group
Group type: COMPARATOR
Intervention: Medication Placebo
Number of subjects: 313
Study 9507235 — intervention group
Group type: EXPERIMENTAL
Intervention: 8:0 + 10:0 diet
Number of subjects: 36
Study 9507235 — intervention group
Group type: EXPERIMENTAL
Intervention: 12:0 diet
Number of subjects: 36
Study 9507235 — intervention group
Group type: EXPERIMENTAL
Intervention: 14:0 diet
Number of subjects: 36
Study 9507235 — intervention group
Group type: EXPERIMENTAL
Intervention: 16:0 diet
Number of subjects: 36
Study 9507235 — intervention group
Group type: EXPERIMENTAL
Intervention: 18:0 diet
Number of subjects: 36
Study 7845799 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate augmentation factor set to low with medium speed of response
Number of subjects: 9
Study 7845799 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate augmentation factor set to medium with fast speed of response
Number of subjects: 9
Study 7845799 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate augmentation factor set to high with fast speed of response
Number of subjects: 9
Study 7845799 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast response time
Number of subjects: 9
Study 7845799 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate augmentation factor
Number of subjects: 9
Study 3132056 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (Datex ABM device for monitoring)
Number of subjects: 40
Study 3132056 — intervention group
Group type: COMPARATOR
Intervention: Control group (video monitor screen turned off)
Number of subjects: 40
Study 3132056 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 31814476 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management support system including a home-BP monitor, self-reports, and BP measurements every evening for eight weeks
Number of subjects: 900
Study 31814476 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 900
Study 31814476 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management support system
Number of subjects: 900
Study 29631810 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib plus hepatic arterial infusion chemotherapy (cisplatin 20 mg/m2 on days 1 and 8 and fluorouracil 330 mg/m2 continuously on days 1-5 and 8-12 of every 28-day cycle)
Number of subjects: 206
Study 29631810 — intervention group
Group type: COMPARATOR
Intervention: sorafenib monotherapy (400 mg orally twice daily)
Number of subjects: 206
Study 29631810 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib plus hepatic arterial infusion chemotherapy
Number of subjects: 206
Study 29631810 — intervention group
Group type: COMPARATOR
Intervention: sorafenib monotherapy
Number of subjects: 206
Study 28854967 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated securement-dressing
Number of subjects: 48
Study 28854967 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture-less securement device
Number of subjects: 48
Study 28854967 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Number of subjects: 48
Study 28854967 — intervention group
Group type: COMPARATOR
Intervention: Standard care (bordered polyurethane dressing and suture)
Number of subjects: 48
Study 26451086 — intervention group
Group type: COMPARATOR
Intervention: Generic MT 5 mg chewable tablets
Number of subjects: 32
Study 26451086 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded Singulair(®) pediatric 5 mg chewable tablets
Number of subjects: 32
Study 24553281 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 percent CPP-ACP cream
Number of subjects: 191
Study 24553281 — intervention group
Group type: COMPARATOR
Intervention: No product (comparison group)
Number of subjects: 191
Study 21047923 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 40
Study 21047923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18808753 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 17154733 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference-focused psychotherapy (TFP)
Number of subjects: 90
Study 17154733 — intervention group
Group type: COMPARATOR
Intervention: Dialectical behavior therapy
Number of subjects: 90
Study 17154733 — intervention group
Group type: COMPARATOR
Intervention: Modified psychodynamic supportive psychotherapy
Number of subjects: 90
Study 14714578 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 62
Study 14714578 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 62
Study 14714578 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 62
Study 14714578 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 62
Study 11060420 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 1 Elastic Compression Stockings (pressure at the ankle 10 to 15 mmHg)
Number of subjects: 341
Study 11060420 — intervention group
Group type: COMPARATOR
Intervention: Placebo Stockings (pressure at the ankle 3 to 6 mmHg)
Number of subjects: 341
Study 8941023 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized meal consumption
Number of subjects: 8
Study 8941023 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of rt-PA
Number of subjects: 8
Study 8941023 — intervention group
Group type: COMPARATOR
Intervention: Abstaining from food
Number of subjects: 8
Study 1357924 — intervention group
Group type: EXPERIMENTAL
Intervention: Protopam chloride (1,000 mg intravenously)
Number of subjects: 61
Study 1357924 — intervention group
Group type: EXPERIMENTAL
Intervention: Protopam chloride (oral and parenteral administration)
Number of subjects: 61
Study 1357924 — intervention group
Group type: EXPERIMENTAL
Intervention: Protopam chloride with electrical stimulation of the spinal cord
Number of subjects: 61
Study 1357924 — intervention group
Group type: EXPERIMENTAL
Intervention: Protopam chloride without electrical stimulation of the spinal cord
Number of subjects: 61
Study 1357924 — intervention group
Group type: EXPERIMENTAL
Intervention: Protopam chloride (large doses)
Number of subjects: 61
Study 1357924 — intervention group
Group type: EXPERIMENTAL
Intervention: Protopam chloride
Number of subjects: 61
Study 30857448 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral squamous cell carcinoma (OSCC) patients
Number of subjects: 60
Study 30857448 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral leukoplakia (OL) patients
Number of subjects: 60
Study 30857448 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 60
Study 30094810 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually configured wheelchair and skin protection cushion
Number of subjects: 258
Study 30094810 — intervention group
Group type: COMPARATOR
Intervention: Facility‐provided wheelchair and skin protection cushion
Number of subjects: 258
Study 26938218 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS1 gene expression levels
Number of subjects: 0
Study 26938218 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs rs10206976 and rs12613336
Number of subjects: 0
Study 26938218 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-metabolite interaction network analysis
Number of subjects: 0
Study 24373019 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidafenacin 0.1 mg twice daily (group A)
Number of subjects: 162
Study 24373019 — intervention group
Group type: COMPARATOR
Intervention: Propiverine 20 mg once daily (group B)
Number of subjects: 162
Study 23086050 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaboration on a given case
Number of subjects: 0
Study 23086050 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 23086050 — intervention group
Group type: EXPERIMENTAL
Intervention: Develop their own case
Number of subjects: 0
Study 23086050 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaborate on a self‐developed case
Number of subjects: 0
Study 22406705 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene 8 mg/day for 8 weeks
Number of subjects: 30
Study 22406705 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 30
Study 18077928 — intervention group
Group type: EXPERIMENTAL
Intervention: gemifloxacin 320 mg/tablet (test product)
Number of subjects: 24
Study 18077928 — intervention group
Group type: COMPARATOR
Intervention: factive 320 mg/tablet (reference product)
Number of subjects: 24
Study 15643181 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG (81 mg, 6 weekly instillations)
Number of subjects: 168
Study 15643181 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin (50 mg, 8 weekly instillations)
Number of subjects: 168
Study 15643181 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 168
Study 15643181 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin
Number of subjects: 168
Study 15643181 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG and Epirubicin
Number of subjects: 168
Study 11862370 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 18
Study 11862370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10194744 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-CARES program
Number of subjects: 0
Study 7477743 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (CDP-choline)
Number of subjects: 0
Study 7477743 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 2105638 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) 1,200 mg/d for 16 weeks
Number of subjects: 30
Study 2105638 — intervention group
Group type: COMPARATOR
Intervention: Control group (observation without changes in prescription)
Number of subjects: 30
Study 2105638 — intervention group
Group type: EXPERIMENTAL
Intervention: SCG group (responders)
Number of subjects: 30
Study 6975168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (80 mg trimethoprim and 400 mg sulfamethoxazole)
Number of subjects: 10
Study 6975168 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-tri-famole (80 mg trimethoprim and 400 mg sulfamoxole)
Number of subjects: 10
Study 6975168 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole and Co-tri-famole
Number of subjects: 10
Study 31665467 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidative radiotherapy (more than 50 Gy)
Number of subjects: 228
Study 31665467 — intervention group
Group type: COMPARATOR
Intervention: Palliative radiotherapy (less than 50 Gy)
Number of subjects: 228
Study 31665467 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastasectomy for disease consolidation
Number of subjects: 228
Study 31665467 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy for disease consolidation
Number of subjects: 228
Study 31487442 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (3 months, 3 sessions per week, 1 hour each)
Number of subjects: 60
Study 31487442 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 60
Study 31487442 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (after 2 months post-intervention)
Number of subjects: 60
Study 31487442 — intervention group
Group type: COMPARATOR
Intervention: Control group (after 2 months post-intervention)
Number of subjects: 60
Study 28276980 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine cravings (induced via abstinence, cue exposure, and imagery)
Number of subjects: 55
Study 28276980 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no caffeine cravings)
Number of subjects: 55
Study 23919432 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenon block
Number of subjects: 63
Study 23919432 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (1 μg·kg(‐1))
Number of subjects: 63
Study 23181640 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase (HAase) injection (20,000 turbidity-reducing units)
Number of subjects: 160
Study 23181640 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 160
Study 19261295 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapropterin dihydrochloride, 20 mg/kg/d for 10 weeks
Number of subjects: 46
Study 19261295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 17684167 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora diabetes intervention (culturally specific participative group education, telephone contact, and follow-up with health behavior change postcards)
Number of subjects: 150
Study 17684167 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study 15120808 — intervention group
Group type: EXPERIMENTAL
Intervention: Predischarge carvedilol initiation
Number of subjects: 363
Study 15120808 — intervention group
Group type: COMPARATOR
Intervention: Postdischarge initiation of beta-blockade
Number of subjects: 363
Study 11687357 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐piece acrylic IOL
Number of subjects: 87
Study 11687357 — intervention group
Group type: COMPARATOR
Intervention: PMMA IOL
Number of subjects: 87
Study 11687357 — intervention group
Group type: COMPARATOR
Intervention: Silicone IOL
Number of subjects: 87
Study 9153532 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous form of the 6-base intronic insertion in endoglin gene
Number of subjects: 103
Study 9153532 — intervention group
Group type: COMPARATOR
Intervention: Control group (202 controls)
Number of subjects: 103
Study 8265301 — intervention group
Group type: EXPERIMENTAL
Intervention: Sn-mesoporphyrin (SnMP) at a dose of 6 mumol/kg body weight
Number of subjects: 517
Study 8265301 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 517
Study 3666079 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing at high frequencies (metronome set at 160 beats per minute)
Number of subjects: 9
Study 3666079 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing at low frequencies (metronome set at 46 beats per minute)
Number of subjects: 9
Study 3666079 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing at high frequencies (metronome set at 100 beats per minute)
Number of subjects: 9
Study 3666079 — intervention group
Group type: EXPERIMENTAL
Intervention: All chewing rates
Number of subjects: 9
Study 31854465 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 30
Study 31854465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30887496 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone
Number of subjects: 29
Study 30887496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 28363133 — intervention group
Group type: EXPERIMENTAL
Intervention: Step Aerobics (SA)
Number of subjects: 42
Study 28363133 — intervention group
Group type: EXPERIMENTAL
Intervention: Stability Ball (SB)
Number of subjects: 42
Study 28363133 — intervention group
Group type: COMPARATOR
Intervention: Control (Ceramic Class)
Number of subjects: 42
Study 26079196 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week Doing Me! intervention (n = 30)
Number of subjects: 60
Study 26079196 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (n = 30)
Number of subjects: 60
Study 23648800 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of total AGEs, LWM‐AGEs, and HWM‐AGEs; cathepsin B activity in plasma and neutrophils
Number of subjects: 102
Study 23648800 — intervention group
Group type: EXPERIMENTAL
Intervention: HWM‐AGEs
Number of subjects: 102
Study 23648800 — intervention group
Group type: EXPERIMENTAL
Intervention: LMW‐AGEs
Number of subjects: 102
Study 23648800 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing levels of HWM‐AGEs and LMW‐AGEs
Number of subjects: 102
Study 23648800 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma level of LMW‐AGEs
Number of subjects: 102
Study 21357906 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone, 25 mg/d for 2 weeks followed by fluticasone propionate nasal drops, 400 µg twice daily for 8 weeks and fluticasone propionate nasal spray, 200 µg twice daily for 18 weeks
Number of subjects: 60
Study 21357906 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks followed by fluticasone propionate nasal drops, 400 µg twice daily for 8 weeks and fluticasone propionate nasal spray, 200 µg twice daily for 18 weeks
Number of subjects: 60
Study 19220069 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacist-led intervention
Number of subjects: 174
Study 19220069 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 174
Study 17267370 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based support groups (telesupport)
Number of subjects: 103
Study 17267370 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 103
Study 15018279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exposure to bright light
Number of subjects: 0
Study 15018279 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exposure to lower light levels and darkness
Number of subjects: 0
Study 11227205 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish applied every 8 weeks for 21 months
Number of subjects: 33
Study 11227205 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish applied every 8 weeks for 21 months
Number of subjects: 33
Study 9039155 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium supplementation (1500 mg of calcium per day)
Number of subjects: 20
Study 9039155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8341042 — intervention group
Group type: EXPERIMENTAL
Intervention: .85 g/kg alcohol
Number of subjects: 4
Study 8341042 — intervention group
Group type: COMPARATOR
Intervention: Control beverage (ginger ale)
Number of subjects: 4
Study 3669071 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal commitment (parents asked for a verbal promise)
Number of subjects: 89
Study 3669071 — intervention group
Group type: COMPARATOR
Intervention: Treatment choice (parents allowed to choose between two antibiotics)
Number of subjects: 89
Study 3669071 — intervention group
Group type: COMPARATOR
Intervention: Treatment choice (parents not allowed to choose)
Number of subjects: 89
Study 30430343 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 117
Study 30430343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 30430343 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 117
Study 28821290 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine mouthwash
Number of subjects: 0
Study 28821290 — intervention group
Group type: COMPARATOR
Intervention: 0.12% Chlorhexidine mouthwash
Number of subjects: 0
Study 28821290 — intervention group
Group type: COMPARATOR
Intervention: 0.06% Chlorhexidine mouthwash
Number of subjects: 0
Study 26035186 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 469
Study 26035186 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 15 mg
Number of subjects: 469